---
document_datetime: 2025-12-18 11:54:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_en.pdf
document_name: saphnelo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8549393
conversion_datetime: 2026-01-03 12:34:24.0862
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging                           | Content (concentration)   | Pack size            |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------------------------------|---------------------------|----------------------|
| EU/1/21/1623/001 | Saphnelo          | 300 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)                                  | 2 ml (150 mg/ml)          | 1 vial               |
| EU/1/21/1623/002 | Saphnelo          | 120 mg     | Solution for injection                | Subcutaneous use          | Pre-filled syringe (glass)                    | 0.8 ml (150 mg/ml)        | 1 pre-filled syringe |
| EU/1/21/1623/003 | Saphnelo          | 120 mg     | Solution for injection                | Subcutaneous use          | Pre-filled syringe (glass) in pre- filled pen | 0.8 ml (150 mg/ml)        | 1 pre-filled pen     |